DAVID WARNOCK, MD
Director of the Division of Nephrology
Professor of Medicine and Physiology
University of Alabama at Birmingham
Birmingham, AL USA

David G. Warnock, MD is the Director of the Division of Nephrology and Professor of Medicine and Physiology at the University of Alabama at Birmingham. He graduated from the University of California at Berkeley and received his MD degree from the University of California, San Francisco. His clinical training was completed at the University of California, San Francisco, including a 1 year research fellowship with Isidore Edelman, MD in the Cardiovascular Research Institute.

Following a fellowship with Maurice Burg, MD at the NIH, Dr. Warnock returned to UCSF as a faculty member. He served as the Section Chief at the San Francisco VA Medical Center during the last 5 years of his appointment at UCSF. Following a sabbatical with Bernard Rossier, MD at the Institute of Pharmacology in Lausanne, Switzerland, Dr. Warnock was recruited to UAB as the Director of Nephrology in 1988. Since May 1, 2005, Dr. Warnock has also served at the Director of the Office of Human Research at UAB.

Dr. Warnock's research interests include acid-base physiology, sodium transport mechanisms, chronic kidney disease, and inherited renal diseases. He is a member of the American Society for Clinical Investigation, American Association of Physicians, American Physiologic Society, ASN, NFK and ISN. He is currently serving as the President of the National Kidney Foundation.

Society Memberships:
• American Society of Clinical Investigation
• American Association of Physicians
• National Kidney Foundation President

Research/Clinical Interest:
Renal REGARDS, Fabry Registry, Inherited Disease of Electrolyte Transport

My focus is on the factors, genetic and environmental that contribute to hypertension and chronic kidney disease. The spectrum extends from basic studies of salt and water transport systems to population based studies of the prevalence of CKD and the association with stroke and heart disease. We currently have an approved ancillary study of the REGARDS project; a prospective cohort evaluation of 30,000 participants 5 yrs of age to examine the effects of anemia and chronic kidney disease on the incidence of stroke and heart disease. Another are focuses on inherited disorders of renal function, with a current emphasis on the renal manifestations of Fabry disease. Over 40 patients with Fabry disease have been identified in Alabama and 20 of them have been started on Enzyme Replacement Therapy.

Selected Publications:
• Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG.
Time-Dependent Associations between Indices of Iron Store and Mortality in Hemodialysis Patients.
J Am Soc Nephrol. 2005 Jul
• Warnock DG. Fabry disease: diagnosis and management, with emphasis on the renal manifestations.
Curr Opin Nephrol Hypertens. 2005 Mar;14(2):87-95.
• Meneton P, Loffing J, Warnock DG. Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule. Am J Physiol Renal Physiol. 2004 Oct;287(4):F593-601.
• Warnock DG. Renal genetic disorders related to K+ and Mg2+.
Annu Rev Physiol. 2002;64:845-76.